Ironwood Pharmaceuticals IRWD Accrued Research And Development Expense Current
Accrued Research And Development Expense Current at other companies
Other financials
Where this comes from
Reported directly by Ironwood Pharmaceuticals in its filing.
Tagged under the XBRL concept irwd:AccruedResearchAndDevelopmentExpenseCurrent.
The official record: Ironwood Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ironwood Pharmaceuticals's accrued research and development expense current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ironwood Pharmaceuticals's accrued research and development expense current?
- Ironwood Pharmaceuticals (IRWD) reported accrued research and development expense current of $2.04M in Q1 2026.
- How has Ironwood Pharmaceuticals's accrued research and development expense current changed year-over-year?
- Ironwood Pharmaceuticals's accrued research and development expense current decreased by 63.7% year-over-year, from $5.63M to $2.04M.
- What is the long-term trend for Ironwood Pharmaceuticals's accrued research and development expense current?
- Over 5 years (2020 to 2025), Ironwood Pharmaceuticals's accrued research and development expense current has grown at a 10.7% compound annual growth rate (CAGR), from $1.9M to $3.15M.
- What does accrued research and development expense current mean?
- This represents the estimated liability for research and development activities that have been performed but not yet invoiced or paid by the company. It reflects the short-term financial commitment to ongoing clinical trials, drug development programs, and scientific research initiatives. Monitoring this helps investors gauge the near-term cash requirements for the company's innovation pipeline.